[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer

Richard Laforest; Suzanne E. Lapi; Reiko Oyama; Ron Bose; Adel Tabchy; Bernadette V. Marquez-Nostra; Jennifer Burkemper; Brian D. Wright; Jennifer Frye; Sarah Frye; Barry A. Siegel; Farrokh Dehdashti

doi:10.1007/s11307-016-0951-z

[⁸⁹Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer

Richard Laforest, Suzanne E. Lapi, Reiko Oyama, Ron Bose, Adel Tabchy, Bernadette V. Marquez-Nostra, Jennifer Burkemper, Brian D. Wright, Jennifer Frye, Sarah Frye, Barry A. Siegel, Farrokh Dehdashti

Research output: Contribution to journal › Article › peer-review

111 Scopus citations

Abstract

Purpose: The purpose of the present study is to evaluate safety, human radiation dosimetry, and optimal imaging time of [⁸⁹Zr]trastuzumab in patients with HER2-positive breast cancer. Procedures: Twelve women with HER2-positive breast cancer underwent [⁸⁹Zr]trastuzumab positron emission tomography (PET)/X-ray computed tomography (CT) twice within 7 days post-injection. Biodistribution data from whole-torso PET/CT images and organ time-activity curves were created using data from all patients. Human dosimetry was calculated using OLINDA with the adult female model. Results: High-quality images and the greatest tumor-to-nontumor contrast were achieved with images performed 5 ± 1 day post-injection. Increased [⁸⁹Zr]trastuzumab uptake was seen in at least one known lesion in ten patients. The liver was the dose-limiting organ (retention of ∼12 % of the injected dose and average dose of 1.54 mSv/MBq). The effective dose was 0.47 mSv/MBq. No adverse effects of [⁸⁹Zr]trastuzumab were encountered. Conclusion: [⁸⁹Zr]trastuzumab was safe and optimally imaged at least 4 days post-injection. The liver was the dose-limiting organ.

Original language	English
Pages (from-to)	952-959
Number of pages	8
Journal	Molecular Imaging and Biology
Volume	18
Issue number	6
DOIs	https://doi.org/10.1007/s11307-016-0951-z
State	Published - Dec 1 2016

Keywords

Dosimetry
HER2
PET imaging
Trastuzumab
Zirconium-89

Access to Document

10.1007/s11307-016-0951-z

Cite this

Laforest, R., Lapi, S. E., Oyama, R., Bose, R., Tabchy, A., Marquez-Nostra, B. V., Burkemper, J., Wright, B. D., Frye, J., Frye, S., Siegel, B. A., & Dehdashti, F. (2016). [⁸⁹Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. Molecular Imaging and Biology, 18(6), 952-959. https://doi.org/10.1007/s11307-016-0951-z

@article{9e27973a031641d8a6ff6533559fa732,

title = "[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer",

abstract = "Purpose: The purpose of the present study is to evaluate safety, human radiation dosimetry, and optimal imaging time of [89Zr]trastuzumab in patients with HER2-positive breast cancer. Procedures: Twelve women with HER2-positive breast cancer underwent [89Zr]trastuzumab positron emission tomography (PET)/X-ray computed tomography (CT) twice within 7 days post-injection. Biodistribution data from whole-torso PET/CT images and organ time-activity curves were created using data from all patients. Human dosimetry was calculated using OLINDA with the adult female model. Results: High-quality images and the greatest tumor-to-nontumor contrast were achieved with images performed 5 ± 1 day post-injection. Increased [89Zr]trastuzumab uptake was seen in at least one known lesion in ten patients. The liver was the dose-limiting organ (retention of ∼12 % of the injected dose and average dose of 1.54 mSv/MBq). The effective dose was 0.47 mSv/MBq. No adverse effects of [89Zr]trastuzumab were encountered. Conclusion: [89Zr]trastuzumab was safe and optimally imaged at least 4 days post-injection. The liver was the dose-limiting organ.",

keywords = "Dosimetry, HER2, PET imaging, Trastuzumab, Zirconium-89",

author = "Richard Laforest and Lapi, {Suzanne E.} and Reiko Oyama and Ron Bose and Adel Tabchy and Marquez-Nostra, {Bernadette V.} and Jennifer Burkemper and Wright, {Brian D.} and Jennifer Frye and Sarah Frye and Siegel, {Barry A.} and Farrokh Dehdashti",

note = "Publisher Copyright: {\textcopyright} 2016, World Molecular Imaging Society.",

year = "2016",

month = dec,

day = "1",

doi = "10.1007/s11307-016-0951-z",

language = "English",

volume = "18",

pages = "952--959",

journal = "Molecular Imaging and Biology",

issn = "1536-1632",

number = "6",

}

Laforest, R, Lapi, SE, Oyama, R, Bose, R, Tabchy, A, Marquez-Nostra, BV, Burkemper, J, Wright, BD, Frye, J, Frye, S, Siegel, BA & Dehdashti, F 2016, '[⁸⁹Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer', Molecular Imaging and Biology, vol. 18, no. 6, pp. 952-959. https://doi.org/10.1007/s11307-016-0951-z

TY - JOUR

T1 - [89Zr]Trastuzumab

T2 - Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer

AU - Laforest, Richard

AU - Lapi, Suzanne E.

AU - Oyama, Reiko

AU - Bose, Ron

AU - Tabchy, Adel

AU - Marquez-Nostra, Bernadette V.

AU - Burkemper, Jennifer

AU - Wright, Brian D.

AU - Frye, Jennifer

AU - Frye, Sarah

AU - Siegel, Barry A.

AU - Dehdashti, Farrokh

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Purpose: The purpose of the present study is to evaluate safety, human radiation dosimetry, and optimal imaging time of [89Zr]trastuzumab in patients with HER2-positive breast cancer. Procedures: Twelve women with HER2-positive breast cancer underwent [89Zr]trastuzumab positron emission tomography (PET)/X-ray computed tomography (CT) twice within 7 days post-injection. Biodistribution data from whole-torso PET/CT images and organ time-activity curves were created using data from all patients. Human dosimetry was calculated using OLINDA with the adult female model. Results: High-quality images and the greatest tumor-to-nontumor contrast were achieved with images performed 5 ± 1 day post-injection. Increased [89Zr]trastuzumab uptake was seen in at least one known lesion in ten patients. The liver was the dose-limiting organ (retention of ∼12 % of the injected dose and average dose of 1.54 mSv/MBq). The effective dose was 0.47 mSv/MBq. No adverse effects of [89Zr]trastuzumab were encountered. Conclusion: [89Zr]trastuzumab was safe and optimally imaged at least 4 days post-injection. The liver was the dose-limiting organ.

AB - Purpose: The purpose of the present study is to evaluate safety, human radiation dosimetry, and optimal imaging time of [89Zr]trastuzumab in patients with HER2-positive breast cancer. Procedures: Twelve women with HER2-positive breast cancer underwent [89Zr]trastuzumab positron emission tomography (PET)/X-ray computed tomography (CT) twice within 7 days post-injection. Biodistribution data from whole-torso PET/CT images and organ time-activity curves were created using data from all patients. Human dosimetry was calculated using OLINDA with the adult female model. Results: High-quality images and the greatest tumor-to-nontumor contrast were achieved with images performed 5 ± 1 day post-injection. Increased [89Zr]trastuzumab uptake was seen in at least one known lesion in ten patients. The liver was the dose-limiting organ (retention of ∼12 % of the injected dose and average dose of 1.54 mSv/MBq). The effective dose was 0.47 mSv/MBq. No adverse effects of [89Zr]trastuzumab were encountered. Conclusion: [89Zr]trastuzumab was safe and optimally imaged at least 4 days post-injection. The liver was the dose-limiting organ.

KW - Dosimetry

KW - HER2

KW - PET imaging

KW - Trastuzumab

KW - Zirconium-89

UR - http://www.scopus.com/inward/record.url?scp=84965057989&partnerID=8YFLogxK

U2 - 10.1007/s11307-016-0951-z

DO - 10.1007/s11307-016-0951-z

M3 - Article

C2 - 27146421

AN - SCOPUS:84965057989

SN - 1536-1632

VL - 18

SP - 952

EP - 959

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

IS - 6

ER -

[⁸⁹Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this